Pure MHC, LLC is a discovery and development company with platform technology and expertise in disease-specific (HLA Class I and Class II) target identification and validation, as well as immunotherapeutic drug development for cancer, infectious, and autoimmune diseases. Pure MHC provides collaborative support to researchers in epitope validation, development, and therapeutic exploitation through expansive HLA experience, and expertise in mass spectrometry, proteomics, peptidomics, informatics, tissue culture, epitope screening & validation, peptide binding, HLA extraction, as well as the transfection, production, and purification of the company’s proprietary soluble HLA proteins.